Definium Therapeutics is trading 6.16% higher at $32.23, rebounding alongside risk-sensitive stocks after Thursday’s sell-off. - Shares declined 7.16% on November 5. - No new company-specific announcement was identified for November 6; the latest company news was a November 4 announcement of Phase 3 data presentations. - Reuters reported the Nasdaq opened higher as chip stocks recovered some losses. The October jobs report showed 165,000 jobs added versus 65,000 expected.